Latest & greatest articles for warfarin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on warfarin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on warfarin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for warfarin

121. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis

A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis 22561965 2012 07 03 2012 09 11 2016 12 15 1535-4970 186 1 2012 Jul 01 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. 88-95 10.1164/rccm.201202-0314OC Animal and human studies support the importance of the coagulation cascade in pulmonary fibrosis. In a cohort of subjects with progressive (...) idiopathic pulmonary fibrosis (IPF), we tested the hypothesis that treatment with warfarin at recognized therapeutic doses would reduce rates of mortality, hospitalization, and declines in FVC. This was a double-blind, randomized, placebo-controlled trial of warfarin targeting an international normalized ratio of 2.0 to 3.0 in patients with IPF. Subjects were randomized in a 1:1 ratio to warfarin or matching placebo for a planned treatment period of 48 weeks. International normalized ratios were

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

122. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding.

Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. CONTEXT: The need for anticoagulation after surgical aortic valve replacement (AVR) with biological prostheses is not well examined. OBJECTIVE: To perform a nationwide study of the association of warfarin treatment with the risk of thromboembolic complications, bleeding incidents, and cardiovascular deaths after bioprosthetic AVR surgery (...) . DESIGN, SETTING, AND PARTICIPANTS: Through a search in the Danish National Patient Registry, 4075 patients were identified who had bioprosthetic AVR surgery performed between January 1, 1997, and December 31, 2009. Concomitant comorbidity and medication were retrieved. Poisson regression models were used to determine risk. MAIN OUTCOME MEASURES: Incidence rate ratios (IRRs) of strokes, thromboembolic events, cardiovascular deaths, and bleeding incidents by discontinuing warfarin as opposed

JAMA2012

123. Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial

Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial 23033226 2012 10 03 2013 02 27 2013 11 21 1875-9114 32 10 2012 Oct Pharmacotherapy Pharmacotherapy Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial. 871-9 10.1002/j.1875-9114.2012.01116 To evaluate the impact of a pharmacist-led warfarin patient self-management program on quality (...) of life and anticoagulation control compared with management in a physician-led specialized anticoagulation clinic. Prospective, randomized, controlled, open-label trial. Tertiary care academic medical center. A total of 114 patients aged 18-75 years who were followed at a specialized anticoagulation clinic, had received warfarin for at least 6 months, and were expected to continue warfarin for a minimum of 4 months. All patients attended an educational session on anticoagulation provided by a pharmacist. Patients

EvidenceUpdates2012

124. Review: New oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF.

Review: New oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF. ACP Journal Club. Review: new oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography (...) Citation manager Format Create File 1 selected item: 22986394 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Sep 18;157(6):JC3-2. doi: 10.7326/0003-4819-157-6-201209180-02002. ACP Journal Club. Review: new oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF. . Comment on [Am J Cardiol. 2012

Annals of Internal Medicine2012

125. Warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm.

Warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm. ACP Journal Club: warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation (...) manager Format Create File 1 selected item: 22910961 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Aug 21;157(4):JC2-7. doi: 10.7326/0003-4819-157-4-201208210-02007. ACP Journal Club: warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm. 1 , . 1 Duke University School of Medicine, Durham

Annals of Internal Medicine2012

127. Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial

Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial 22700854 2012 07 17 2012 10 02 2015 11 19 1524-4539 126 3 2012 Jul 17 Circulation Circulation Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. 343-8 10.1161 (...) /CIRCULATIONAHA.111.090464 Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required. The current analysis was undertaken to compare the periprocedural bleeding risk of patients in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial treated with dabigatran and warfarin. Bleeding rates were evaluated from 7 days before until 30 days after invasive

EvidenceUpdates2012

129. Warfarin in Heart Failure.

Warfarin in Heart Failure. Warfarin in heart failure. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 22551103 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 May 17;366(20):1936-8. doi: 10.1056/NEJMe1202504. Epub 2012 May 2. Warfarin in heart failure. , . Comment on [N Engl J Med. 2012] PMID: 22551103 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links You are here: > > PubMed Simple

NEJM2012

130. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis

Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis Agarwal S, Hachamovitch R, Menon V CRD summary This review concluded that the current (...) use of warfarin as a stroke prevention agent in patients with atrial fibrillation was associated with a low rate of residual stroke or systemic embolism, estimated to be 1.66% per year. There were several limitations of the review and analysis so the results and conclusions should be treated with caution Authors' objectives To evaluate the absolute safety and efficacy outcomes in patients with non-valvular atrial fibrillation treated with warfarin for stroke prevention. Searching MEDLINE, EMBASE

DARE.2012

131. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses Pink J, Lane S, Pirmohamed M, Hughes DA Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of dabigatran etexilate and warfarin in patients with non-valvular atrial fibrillation and a moderate-to-high risk of stroke. Dabigatran 110mg

NHS Economic Evaluation Database.2012

132. A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children

A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2012

133. Randomised controlled trial: For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding

Randomised controlled trial: For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you (...) are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing

Evidence-Based Medicine (Requires free registration)2012

134. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Miller CS, Grandi SM, Shimony A, Filion (...) KB, Eisenberg MJ CRD summary The authors concluded that new oral anticoagulants were more efficacious than warfarin in prevention of stroke and systemic embolism in patients with atrial fibrillation, and have a more favourable safety profile. Possibility of missed unpublished studies, unclear levels of bias during review process and scarcity of trial quality information mean that the reliability of these conclusions is difficult to assess. Authors' objectives To compare the efficacy and safety

DARE.2012

135. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices

Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices Ghanbari H, Saint Phard W, Al-Ameri H (...) , Latchamsetty R, Jongnarngsin K, Crawford T, Good E, Chugh A, Oral H, Bogun F, Morady F, Pelosi F CRD summary The authors concluded that the strategy of uninterrupted warfarin therapy throughout pacemaker or implantable cardioverter-defibrillator implantation was associated with decreased risk of bleeding without increasing risk of thromboembolic events. Clinical variations between the included studies and some of the methodological limitations identified mean the authors conclusion may not be reliable

DARE.2012

136. Warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm

Warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm Warfarin and aspirin did not diff... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation Short URL Annals of Internal Medicine ( 2012 ) Volume: 157 , Pages: JC2-7 ST - Warfarin and aspirin did not differ fo Available from or Find this paper at: Abstract QUESTION What are the relative efficacy and safety of warfarin and aspirin in patients (...) with heart failure who are in sinus rhythm? METHODS DESIGN Randomized controlled trial (Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction WARCEF trial). ClinicalTrials.gov NCT00041938. ALLOCATION Concealed.+ BLINDING Blinded+ (patients, clinicians, data collectors, safety committee, and outcome assessors). FOLLOW-UP PERIOD =NON-BREAKING SPACE18 years of age (mean age 61 y, 80% men) who had a left ventricular ejection fraction (LVEF) NON-BREAKING SPACE4, medical conditions with high risk

Annals of Internal Medicine2012

137. Warfarin and aspirin in patients with heart failure and sinus rhythm.

Warfarin and aspirin in patients with heart failure and sinus rhythm. 22551105 2012 05 17 2012 05 24 2016 12 15 1533-4406 366 20 2012 May 17 The New England journal of medicine N. Engl. J. Med. Warfarin and aspirin in patients with heart failure and sinus rhythm. 1859-69 10.1056/NEJMoa1202299 It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm. We designed this trial to determine whether warfarin (with a target (...) international normalized ratio of 2.0 to 3.5) or aspirin (at a dose of 325 mg per day) is a better treatment for patients in sinus rhythm who have a reduced left ventricular ejection fraction (LVEF). We followed 2305 patients for up to 6 years (mean [±SD], 3.5±1.8). The primary outcome was the time to the first event in a composite end point of ischemic stroke, intracerebral hemorrhage, or death from any cause. The rates of the primary outcome were 7.47 events per 100 patient-years in the warfarin group and 7.93

NEJM2012 Full Text: Link to full Text with Trip Pro

138. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. 23036896 2012 11 19 2012 12 10 2015 06 16 1474-547X 380 9855 2012 Nov 17 Lancet (London, England) Lancet Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. 1749-58 10.1016/S0140 (...) -6736(12)60986-6 S0140-6736(12)60986-6 The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at prevention of stroke or systemic embolism, causes less bleeding, and results in lower mortality. We assessed in this trial's participants how results differed according to patients' CHADS(2), CHA(2)DS(2)VASc, and HAS-BLED scores, used to predict the risk of stroke and bleeding. ARISTOTLE was a double-blind

Lancet2012

139. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.

Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. 22130488 2012 01 16 2012 02 07 2015 06 16 1474-547X 379 9811 2012 Jan 14 Lancet (London, England) Lancet Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non (...) -inferiority trial. 123-9 10.1016/S0140-6736(11)61505-5 Treatment of pulmonary embolism with low-molecular-weight heparin and vitamin K antagonists, such as warfarin, is not ideal. We aimed to assess non-inferiority of idrabiotaparinux, a reversible longlasting indirect inhibitor of activated factor X, to warfarin in patients with acute symptomatic pulmonary embolism. In our randomised, double-blind, double-dummy, non-inferiority trial, we enrolled adults with objectively documented acute symptomatic

Lancet2012

140. ROCKET?AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation

ROCKET?AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation RXFILES TRIAL SUMMARY ORIGINALLY PREPARED BY: M JIN, REVISED BY: L KOSAR – UPDATED DECEMBER 2012 – WWW.RXFILES.CA Page 1 of 4 ROCKET-AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation 1 Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in AF BOTTOM LINE In atrial fibrillation (AF) patients with an ? risk of stroke (mean CHADS (...) 2 score 3.5), rivaroxaban 20mg po daily: ? Was non-inferior (i.e. no worse than) to warfarin for ? stroke or systemic embolism ? Had less hemorrhagic strokes, systemic embolism & bleeding (critical, fatal & intracranial) versus warfarin ? Had more drops in hemoglobin =20 g/L, tranfusions, gastrointestinal bleeding, epistaxis & hematuria versus warfarin ? At time of publication, rivaroxaban for AF is approximately $100/month; 15mg, 20mg tablets. ? A Fib, ? Warfarin + monitoring ~$35/month

RxFiles2012